Spine surgery has a reimbursement problem that refuses to go away, and this week it got louder. The American Association of Neurological Surgeons and the Congress of Neurological Surgeons, joined by the North American Spine Society and other national organizations, issued a fresh call for payers to stop denying coverage under CPT code 22853 — the code that covers insertion of titanium or PEEK interbody cages during spinal fusion. This is not the first time the societies have said this. It is the second time in three months, and that alone tells you something about where this is headed.
Back in April and May, the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves put out a position statement making largely the same case: interbody biomechanical devices have been standard practice in cervical fusion for more than two decades, the clinical literature supports them, and payer policies treating them as experimental are out of step with reality. Nothing changed. So the societies came back, this time with sharper language and a wider list of signatories.
The clinical argument itself is not new, and it is not really in dispute among surgeons. Christopher Kauffman, NASS’s first vice president, laid out the practical stakes to Healio: insurers keep leaning on older literature showing structural allografts perform comparably to cages, but allografts are not always available in hospitals and can carry microfractures that cause them to fail. When that happens, patients face a second surgery that a modern cage likely would have avoided. Kauffman’s framing is worth noting because it reframes the debate — this is not cages versus allografts on a spreadsheet, it is what happens to a patient when the material on hand isn’t structurally reliable.
The more interesting detail is where the denials are concentrated: certain Medicare Advantage plans. That’s a specific, addressable target, not a vague complaint about “insurers” as a category. Kauffman was direct about why that matters: a Medicare Advantage plan isn’t legally allowed to restrict access to care beyond what standard Medicare provides. That’s not a clinical argument, it’s a compliance one, and it’s a sharper lever than “the evidence supports us.” The societies have also said they hope CMS takes notice and treats this as an issue worth acting on — which, if it happens, moves the fight from a public-relations exercise into a regulatory one.
That distinction matters. Position statements and op-eds are easy for payers to absorb and ignore. A CMS inquiry into whether Medicare Advantage plans are applying coverage restrictions they’re not entitled to apply is a different kind of pressure entirely, with actual enforcement teeth behind it.
For the industry, the temptation is to read this as background noise. Reimbursement friction in spine is not new, and cervical fusion is about as mature and stable a segment as this market has. That reading undersells what’s happening. The real subject of this fight isn’t a single CPT code. It’s who gets to define standard of care in a field where the clinical consensus and the payer consensus have quietly drifted apart. Every time a specialty society has to publicly argue that a two-decade-old, widely used implant category isn’t experimental, it’s a signal that the reimbursement environment is not stabilizing on its own.
That matters differently depending on where you sit. For manufacturers, it’s a reason to keep clinical evidence packages current and to support societies’ advocacy rather than treat it as someone else’s fight. For distributors and sales organizations, it’s a reminder that the commercial cycle now includes a reimbursement layer that can stall a case regardless of how sound the surgical plan is — documentation and appeals support are no longer a back-office afterthought. For investors, it’s a data point on payer behavior worth tracking rather than dismissing, because cervical fusion was supposed to be the safe, predictable part of the spine market. If it isn’t, nothing in this space really is.
Expect a third statement if this one goes unanswered too.
###
Legal Disclaimer:
Content published on SPINEMarketGroup (thespinemarketgroup.com) is provided for informational purposes only and on an “as is” basis, without warranties of any kind. We do not guarantee the accuracy, completeness, legality, or reliability of any information, images, videos, links, or third-party materials featured on the site. Any views or claims expressed in contributed content or press releases belong to their respective authors or sources. For copyright concerns, factual corrections, or content-related complaints, please contact us directly for review.